loading page

Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake
  • +2
  • Takatsugu Ogata,
  • Yukiya Narita,
  • Kazunari Misawa,
  • Waki Hosoda,
  • Kei Muro
Takatsugu Ogata
Aichi Cancer Center Hospital
Author Profile
Yukiya Narita
Aichi Cancer Center Hospital
Author Profile
Kazunari Misawa
Aichi Cancer Center Hospital
Author Profile
Waki Hosoda
Aichi Cancer Center Hospital
Author Profile
Kei Muro
Aichi Cancer Center Hospital
Author Profile

Abstract

This is the first report of marked improvement of oral intake by third-line nivolumab monotherapy in a gastric cancer patient with insufficient oral intake and European Cooperative Oncology Group performance status 2. We should consider immune checkpoint inhibitors for microsatellite instability-high gastric cancer, regardless of the patient's general condition.

Peer review status:ACCEPTED

20 May 2020Submitted to Clinical Case Reports
21 May 2020Submission Checks Completed
21 May 2020Assigned to Editor
05 Jun 2020Reviewer(s) Assigned
06 Jul 2020Review(s) Completed, Editorial Evaluation Pending
31 Jul 20201st Revision Received
01 Aug 2020Submission Checks Completed
01 Aug 2020Assigned to Editor
01 Aug 2020Review(s) Completed, Editorial Evaluation Pending
03 Aug 2020Reviewer(s) Assigned
24 Aug 2020Editorial Decision: Accept